We are Azafaros

A beacon for people living with severe rare metabolic disorders.

A team of highly experienced industry experts

Azafaros is supported by a syndicate of leading Dutch and Swiss investors. Our clinical candidate AZ-3102 is an orally available azasugar designed to treat the central nervous system and to interfere with the metabolism of glycosphingolipids affecting key disease pathways through a unique dual mode of action.
Azafaros aims to be a beacon for patients living with severe rare genetic diseases and their families.

– Since 2018


Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients